Literature DB >> 10027935

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.

P Ruggenenti1, L Mosconi, F Sangalli, F Casiraghi, V Gambara, G Remuzzi, A Remuzzi.   

Abstract

BACKGROUND: In patients with insulin-dependent diabetes mellitus (IDDM) and overt nephropathy glomerular barrier size-selectivity progressively deteriorates with time and is effectively improved by angiotensin converting enzyme (ACE) inhibition. Whether similar glomerular functional changes develop in proteinuric patients with non-insulin-dependent diabetes mellitus (NIDDM), and whether antihypertensive agents can favorably affect glomerular filtration of macromolecules in these patients, has not been documented yet.
METHODS: We investigated renal hemodynamics and fractional clearance of neutral dextrans of graded sizes, in nine proteinuric patients with NIDDM and renal biopsy findings of typical diabetic glomerulopathy. Six healthy volunteers served as controls. We also investigated the effects of an ACE inhibitor and of a calcium channel blocker, both given in doses targeted to achieve a comparable level of systemic blood pressure control, on glomerular hemodynamics and sieving function. Theoretical analysis of glomerular macromolecule transport was adopted to evaluate intrinsic glomerular membrane permeability properties.
RESULTS: Fractional clearance of large macromolecules (42 to 66 A in radius) was significantly higher in diabetic patients than in controls, and the distribution of membrane pore radii was calculated to be shifted towards larger pore sizes in diabetics (mean radius increased from 55 to 60 A). Despite effective blood pressure control, neither antihypertensive affected glomerular hemodynamics to any significant extent. Fractional clearance of dextrans, as well as of albumin and IgG, and total urinary proteins were not modified by either treatments.
CONCLUSIONS: These data indicate that patients with NIDDM and overt nephropathy develop abnormalities in size-selective function of the glomerular barrier and, at variance to IDDM, such changes were not ameliorated either by ACE inhibition or calcium channel blockade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027935     DOI: 10.1046/j.1523-1755.1999.055003984.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Imaging of the porous ultrastructure of the glomerular epithelial filtration slit.

Authors:  Elena Gagliardini; Sara Conti; Ariela Benigni; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

2.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

Review 3.  The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

Review 4.  Where does albuminuria come from in diabetic kidney disease?

Authors:  Wayne D Comper; Leileata M Russo
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

5.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

Review 6.  Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?

Authors:  Gozewÿn Laverman; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

7.  eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.

Authors:  Tomoki Kosugi; Marcelo Heinig; Takahiro Nakayama; Seiichi Matsuo; Takahiko Nakagawa
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

Review 8.  Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte
Journal:  Nephrology (Carlton)       Date:  2021-01-04       Impact factor: 2.506

9.  Antioxidants in kidney diseases: the impact of bardoxolone methyl.

Authors:  Jorge Rojas-Rivera; Alberto Ortiz; Jesus Egido
Journal:  Int J Nephrol       Date:  2012-06-04

Review 10.  Proteinuria in diabetic nephropathy: treatment and evolution.

Authors:  Ruth C Campbell; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.